Vitamin D receptor agonists induce prostatic acid phosphatase to reduce cell growth and HER-2 signaling in LNCaP-derived human prostate cancer cells
- 1 October 2005
- journal article
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 97 (1-2) , 37-46
- https://doi.org/10.1016/j.jsbmb.2005.06.011
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Tyrosine-317 of p52Shc mediates androgen-stimulated proliferation signals in human prostate cancer cellsOncogene, 2004
- Expression of Concern: HER2 signaling enhances 5′UTR‐mediated translation of c‐Myc mRNAJournal of Cellular Physiology, 2004
- Suppression of LNCaP prostate cancer xenograft tumors by a prostate‐specific protein tyrosine phosphatase, prostatic acid phosphataseThe Prostate, 2003
- ErbB-2 signaling is involved in regulating PSA secretion in androgen-independent human prostate cancer LNCaP C-81 cellsOncogene, 2003
- Establishment and characterization of androgen‐independent human prostate cancer LNCaP cell modelThe Prostate, 2002
- Calcipotriol Inhibits Autocrine Phosphorylation of EGF Receptor in a Calcium-Dependent Manner, a Possible Mechanism for Its Inhibition of Cell Proliferation and Stimulation of Cell DifferentiationBiochemical and Biophysical Research Communications, 2001
- Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cellsOncogene, 2000
- Antiproliferative Effect of 1 ,25-Dihydroxyvitamin D3 in Human Prostate Cancer Cell Line LNCaP Involves Reduction of Cyclin-Dependent Kinase 2 Activity and Persistent G1 AccumulationEndocrinology, 1998
- Androgen receptors in endocrine‐therapy‐resistant human prostate cancerInternational Journal of Cancer, 1991
- Increased epidermal growth factor receptor level in breast cancer cells treated by 1,25-dihydroxyvitamin D3Molecular and Cellular Endocrinology, 1989